After analyzing the multipleriskscaused by theextension of wealthlabel, the author proves thenecessity to lessen the phenomena of wealth labelextension.
Announcing the failure of the latest trial Tuesday, the two companies said they would halt development of Dimebon for all indications and cease an ongoing open-label extension study in Alzheimer's disease.